Sertraline

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instanceOf antidepressant
selective serotonin reuptake inhibitor
gptkbp:approvalYear 1991
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode gptkb:N06AB06
gptkbp:bioavailability 44%
gptkbp:brand gptkb:Lustral
gptkb:Zoloft
gptkbp:CASNumber gptkb:79617-96-2
gptkbp:category gptkb:World_Health_Organization_essential_medicines
antidepressants
gptkbp:chemicalFormula C17H17Cl2N
gptkbp:contraindication concurrent use with MAO inhibitors
allergy to sertraline
gptkbp:discoveredBy gptkb:Pfizer
gptkbp:eliminationHalfLife 26 hours
gptkbp:excretion gptkb:kidney
gptkbp:firstMarketedYear 1991
gptkbp:genericAvailable yes
gptkbp:hasEnantiomer gptkb:(R)-sertraline
gptkb:(S)-sertraline
https://www.w3.org/2000/01/rdf-schema#label Sertraline
gptkbp:interactsWith gptkb:warfarin
gptkb:MAO_inhibitors
gptkb:NSAIDs
gptkb:pimozide
other serotonergic drugs
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction inhibits reuptake of serotonin
gptkbp:metabolism gptkb:desmethylsertraline
liver
gptkbp:molecularWeight 306.23 g/mol
gptkbp:patentedYear 1970s
gptkbp:pregnancyCategory C
C (US)
gptkbp:proteinBinding 98%
gptkbp:PubChem_CID 68617
DB01104
gptkbp:riskOfSerotoninSyndrome yes
gptkbp:routeOfAdministration oral
gptkbp:sideEffect nausea
diarrhea
dizziness
insomnia
dry mouth
sexual dysfunction
gptkbp:UNII QJ0KD7J8U7
gptkbp:usedFor gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:post-traumatic_stress_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
premenstrual dysphoric disorder
gptkbp:bfsParent gptkb:Antidepressants
gptkbp:bfsLayer 6